Top View
- Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge
- Effective Treatment of Apatinib in Desmoplastic Small
- Management of Hepatocellular Carcinoma After Progression on First-Line Systemic Treatment: Defining the Optimal Sequencing Strategy in Second Line and Beyond
- Predictors of Apatinib in the Treatment of Advanced Primary Liver Cancer
- Review of Survival, Safety, and Clinical Outcomes in HER2+ Metastatic Gastric Cancer Following the Administration of Trastuzumabpost- T Trastuzumab Gastric Cancer
- New Agents and Regimens for Diffuse Large B Cell Lymphoma
- Clinical Outcomes and Safety of Apatinib Monotherapy in The
- Apatinib Treatment for KIT- and KDR-Amplified Angiosarcoma: a Case Report Lishu Yang1, Lizhu Liu1, Bo Han1*, Wei Han2 and Meng Zhao3
- Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?
- Successful Treatment of Liver and Abdomen Metastasis of Renal Epithelioid Angiomyolipoma with Apatinib: a Case Report
- Apatinib Mesylate in the Treatment of Advanced Progressed Lung
- Addition of Apatinib to Transarterial Chemoembolization Leads to Improved Outcome in Patients with Intermediate and Advanced Hepatocellular Cancer
- Global Oncology Trend Report a Review of 2015 and Outlook to 2020
- Apatinib in Treating Patients with Recurrent Or Metastatic Nasopharyngeal Carcinoma Who Had Failed Prior Platinum-Based Chemotherapy
- Novel Systemic Therapies for Advanced Gastric Cancer
- Camrelizumab in Combination with Apatinib in Second-Line Or Above Therapy for Advanced Primary Liver Cancer
- HER2/Neu As Target in Gastric Adenocarcinoma
- October 2017 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
- Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice
- Comparative Assessment of Protein Kinase
- WO 2018/073754 Al 26 April 2018 (26.04.2018) W !P O PCT
- Antitumorigenic and Antiangiogenic Efficacy of Apatinib in Liver Cancer
- Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors
- Advances in Targeted Therapy for Esophageal Cancer
- Tan Tanta Cu O La Da Im Un Da Hata Kama
- Apatinib Treatment Efficiently Delays Biochemical-Only Recurrent Ovarian
- January 2018 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
- Highlights from the 2018 Annual Meeting of the American Society of Clinical Oncology
- Apatinib: Get Better Application in Gastric Cancer and Other Cancers
- Pyrotinib in the Treatment of Refractory HER2-Positive
- Clinical Use of Trastuzumab Combined with Different Chemotherapy
- Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers
- Study Protocol and Statistical Analysis Plan
- Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced
- Apatinib for Advanced Sarcoma: Results from Multiple Institutions' Off
- Efficacy and Safety of Sorafenib Versus Apatinib in the Treatment of Intermediate and Advanced Hepatocellular Carcinoma: a Comparative Retrospective Study
- Dicer Increases the Indication for Trastuzumab Treatment in Gastric
- Apatinib, a Novel VEGFR-2 Tyrosine Kinase Inhibitor, for Relapsed and Refractory Nasopharyngeal Carcinoma: Data from an Open-Label, Single-Arm, Exploratory Study
- Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters